Concomitant EGFR mutation and EML4-ALK gene fusion in non-small cell lung cancer. Print this page
5 h+ u$ [ ~( D5 @7 V) _" }5 U9 y, G- o S' l
0 G9 |* n; A6 h \" _Sub-category:
( [4 m9 d5 x% z7 L. EMolecular Targets $ Z. c& }2 y# x! Z4 }: g- h% G
; m7 @3 V/ r0 a' [
! |- G2 F6 v, S/ E+ x/ xCategory:5 Y8 I8 G J3 v1 J1 W3 t8 v/ z
Tumor Biology 7 q( c( d6 h3 u7 z6 [, b
6 \: n; [- ?2 w0 x* d0 r1 t
6 ]: ?) \, E- P5 g$ C& f! \
Meeting:
7 J4 B2 f$ k: j" A2 c2011 ASCO Annual Meeting
8 V' ~, H) N! B1 l$ O0 Q$ N" |$ w
2 f. G% \+ A& h& u" [" Y9 a4 T u# A# S$ R6 E. o+ X' F0 ?
Session Type and Session Title:' q+ B5 @$ G% d; T+ Q
Poster Discussion Session, Tumor Biology # i% e U. S3 V
/ h- ]9 e. I4 {
$ W9 w4 V5 |2 H- Y NAbstract No:
* c" O0 S7 @9 e/ `, k( B10517 7 K: `6 l% s! w7 o: v
( W+ W Y% O! ~" N
~+ m: {3 H6 Q+ W/ e5 k! p
Citation: g. Z1 d1 j" q- T
J Clin Oncol 29: 2011 (suppl; abstr 10517)
2 D# T) ]0 j3 }* U$ k0 @
: ?9 x# j( o# b V
1 K$ n* D! v8 Q" Q- AAuthor(s):
* o. U+ Q& \! o) d! h$ ]J. Yang, X. Zhang, J. Su, H. Chen, H. Tian, Y. Huang, C. Xu, Y. L. Wu; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China; Guangdong Lung Cancer Institute, Medical Research Center of Guangdong General Hospital, Guangzhou, China; Guangdong Lung Cancer Institute, Guangzhou, China; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China
6 d. E9 ?' y) y8 t& {: N5 `1 f. c4 G8 d9 i( w' J
# x8 c2 l5 c6 E2 h! A; }' p( I# @1 h$ F+ e' I, z6 O6 j9 U
Abstracts that were granted an exception in accordance with ASCO's Conflict of Interest Policy are designated with a caret symbol (^) here and in the printed Proceedings.
0 a/ ?0 X& q% u) @3 b% m I; Y9 L; I' x0 e
Abstract Disclosures% s7 v L' t% [# }% C; ^1 C
" B# \: A' W' J# `( `" j6 {Abstract:
. A4 E. y* K5 @! [7 O' w4 _# L" k7 g9 a7 z
; M8 m) M" ?) c! j* @6 e
Background: The fusion of the anaplastic lymphoma kinase (ALK) with the echinoderm microtubule-associated protein-like 4 (EML4) and epidermal growth factor receptor (EGFR) mutations are considered mutually exclusive. Advanced non-small cell lung cancer (NSCLC) patients with EML4-ALK did not benefit from EGFR tyrosine kinase inhibitors (TKIs). Methods: Multiplex reverse transcriptase-polymerase chain reaction (RT-PCR) followed by sequencing was performed for EML4-ALK fusion status detection. EGFR and KRAS mutations were determined by direct DNA sequencing. Positive results of EML4-ALK fusion were also confirmed by RACE-coupled PCR sequencing. Results: From April 2010 to January 2011, 412 patients (398 with NSCLC; 14 with SCLC) were tested for mutation status of EGFR, KRAS and EML4-ALK respectively. Frequency of EML4-ALK fusion was 10.6% (42/398) in NSCLC patients. No patients with SCLC were found to have positive EML4-ALK fusion. Frequency of concomitant EGFR and EML4-ALK gene mutations was 1.0% (4/398) in NSCLC patients, and their variants of EML4-ALK gene mutations were Variant 1 (3 patients) and Variant 6 (1 patient); being never smokers, all of them were diagnosed with advanced (3 with stage †W and 1 with stage IIIB) adenocarcinoma harbouring wild type KRAS. Two female stage †W patients with double gene mutations (1 with L858R and Variant 1; 1 with exon19 deletion and Variant 6) received first-line gefitinib which is one kind of EGFR TKIs and achieved partial response. Conclusions: Though being rare events, NSCLC patients harbouring concomitant EGFR mutation and EML4-ALK gene fusion are sensitive to first-line EGFR TKIs. Whether they could also benefit from ALK inhibition after failure to EGFR TKIs warranted further investigation.
1 b! f8 A' n8 b
. f" {0 ~/ i; g/ | $ O# E1 G& b+ i, B1 [
|